Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.47 |
| ▸ | PAOX | Q6QHF9 | 2/20 | 0.46 |
| ▸ | CASP2 | P42575 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | KDM4A | O75164 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.44 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7211184 | 0.93 | PAOX (0.56) | SLC6A5PAOXCASP2L3MBTL1KDM4A | |
| SCHEMBL12829898 | 0.92 | CASP2 (0.46) | SLC6A5PAOXCASP2L3MBTL1KDM4A | |
| SCHEMBL7204674 | 0.92 | CASP2 (0.52) | SLC6A5PAOXCASP2L3MBTL1KDM4A | |
| SCHEMBL27176325 | 0.92 | SLC6A5 (0.49) | SLC6A5PAOXCASP2L3MBTL1KDM4A | |
| SCHEMBL24761185 | 0.90 | SLC6A5 (0.51) | SLC6A5PAOXCASP2KDM4AHIF1A | |
| SCHEMBL6745342 | 0.90 | TSHR (0.54) | SLC6A5PAOXCASP2KDM4AHIF1A | |
| SCHEMBL6745339 | 0.90 | TSHR (0.54) | SLC6A5PAOXCASP2KDM4AHIF1A | |
| SCHEMBL14360491 | 0.89 | PAOX (0.53) | PAOXCASP2TSHRCYP2C19MEN1 | |
| SCHEMBL9506604 | 0.88 | SLC6A5 (0.59) | SLC6A5PAOXKDM4AHIF1ATET2 | |
| SCHEMBL27406932 | 0.86 | NAAA (0.59) | SLC6A5PAOXCASP2KDM4AHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12286579-B2 | Fire-retardant oriented strand board | Arxada, LLC (US) | 2025-04-29 | — | — | US | disclosed |
| US-20220340816-A1 | Fire-Retardant Oriented Strand Board | Arxada, LLC | 2022-10-27 | — | — | US | disclosed |
| US-11414602-B2 | Fire-retardant oriented strand board | Arxada, LLC (US) | 2022-08-16 | — | — | US | disclosed |
| US-20210330792-A1 | (BACTERIO)CHLOROPHYLL PHOTOSENSITIZERS FOR TREATMENT OF EYE DISEASES AND DISORDERS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2021-10-28 | — | — | US | disclosed |
| WO-2021125279-A1 | CHEMICALLY CROSSLINKED ALGINATE GEL FIBER | 持田製薬株式会社 | 2021-06-24 | — | — | WO | disclosed |
| US-20200392412-A1 | Fire-Retardant Oriented Strand Board | LONZA, LLC | 2020-12-17 | — | — | US | disclosed |
| CN-103930108-A | (Bacterio)chlorophyll photosensitizers for treatment of eye diseases and disorders | YEDA RES & DEV | 2014-07-16 | — | — | CN | disclosed |
| EP-1100816-B1 | AEROTHRICIN ANALOGS, THEIR PREPARATION AND USE | BASILEA PHARMACEUTICA AG (CH) | 2007-08-08 | — | — | EP | disclosed |
| EP-1251827-B1 | NASALLY ADMINISTRABLE ANTIFUNGAL CYCLIC PEPTIDE COMPOSITIONS | BASILEA PHARMACEUTICA AG (CH) | 2004-05-26 | — | — | EP | disclosed |
| US-6489440-B1 | Cyclic compounds | BASILEA PHARMACEUTICA AG (CH) | 2002-12-03 | — | — | US | disclosed |
| EP-1251827-A2 | NASALLY ADMINISTRABLE CYCLIC PEPTIDE COMPOSITIONS | Basilea Pharmaceutica AG (CH) | 2002-10-30 | — | — | EP | disclosed |
| US-20010038824-A1 | Intranasal cyclic peptide formulations | BASILEA PHARMACEUTICA AG (CH) | 2001-11-08 | — | — | US | disclosed |
| WO-2001052894-A2 | NASALLY ADMINISTRABLE CYCLIC PEPTIDE COMPOSITIONS | BASILEA PHARMACEUTICA AG (CH) | 2001-07-26 | — | — | WO | disclosed |
| EP-1100816-A1 | AEROTHRICIN ANALOGS, THEIR PREPARATION AND USE | F. HOFFMANN-LA ROCHE AG (CH) | 2001-05-23 | — | — | EP | disclosed |
| WO-2000005251-A1 | AEROTHRICIN ANALOGS, THEIR PREPARATION AND USE | F. HOFFMANN-LA ROCHE AG (CH) | 2000-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210330792-A1 | (BACTERIO)CHLOROPHYLL PHOTOSENSITIZERS FOR TREATMENT OF EYE DISEASES AND DISORDERS | PPOX, PPIB, PPIA | SLC6A5 1596/4885PAOX 66/4885CASP2 3070/4885 |
| US-20010038824-A1 | Intranasal cyclic peptide formulations | VIP, NPPA, SSTR5 | SLC6A5 868/4885PAOX 1895/4885CASP2 2432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.